Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | hydroxyprostaglandin dehydrogenase 15-(NAD) | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | steroid dehydrogenase, putative | hydroxyprostaglandin dehydrogenase 15-(NAD) | 266 aa | 216 aa | 22.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | AStacin protease | 0.0031 | 0.5537 | 0.5537 |
Loa Loa (eye worm) | hypothetical protein | 0.0014 | 0.1545 | 0.1545 |
Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.1932 | 0.1932 |
Plasmodium falciparum | cysteine repeat modular protein 1 | 0.0012 | 0.1043 | 0.5 |
Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.0012 | 0.1043 | 0.5 |
Echinococcus multilocularis | laminin | 0.0016 | 0.1932 | 0.0993 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.1043 | 0.1043 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.0016 | 0.1932 | 1 |
Brugia malayi | Low-density lipoprotein receptor repeat class B containing protein | 0.0014 | 0.1545 | 0.7997 |
Brugia malayi | Fibulin-1 precursor | 0.0016 | 0.1932 | 1 |
Schistosoma mansoni | subfamily M12A unassigned peptidase (M12 family) | 0.005 | 1 | 1 |
Onchocerca volvulus | 0.0012 | 0.1043 | 0.6749 | |
Leishmania major | hypothetical protein, conserved | 0.0012 | 0.1043 | 0.5 |
Loa Loa (eye worm) | bone morphogenetic protein 1b | 0.005 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0014 | 0.1545 | 0.1545 |
Toxoplasma gondii | kringle domain-containing protein | 0.0012 | 0.1043 | 0.5397 |
Loa Loa (eye worm) | TK/ROR protein kinase | 0.0012 | 0.1043 | 0.1043 |
Onchocerca volvulus | Arrow homolog | 0.0014 | 0.1545 | 1 |
Echinococcus multilocularis | Tolloid protein 1 | 0.005 | 1 | 1 |
Echinococcus granulosus | laminin | 0.0016 | 0.1932 | 0.0993 |
Loa Loa (eye worm) | hypothetical protein | 0.002 | 0.2942 | 0.2942 |
Loa Loa (eye worm) | hypothetical protein | 0.0048 | 0.9516 | 0.9516 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0012 | 0.1043 | 0.5 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.0016 | 0.1932 | 1 |
Loa Loa (eye worm) | multiple epidermal growth factor-like domains 6 | 0.0016 | 0.1932 | 0.1932 |
Echinococcus multilocularis | fibrillin 1 | 0.0016 | 0.1932 | 0.0993 |
Brugia malayi | Calcium binding EGF domain containing protein | 0.0016 | 0.1932 | 1 |
Brugia malayi | Kringle domain containing protein | 0.0012 | 0.1043 | 0.5397 |
Loa Loa (eye worm) | low-density lipoprotein receptor repeat class B containing protein | 0.0014 | 0.1545 | 0.1545 |
Schistosoma mansoni | egf-like domain protein | 0.0014 | 0.1545 | 0.0561 |
Brugia malayi | Protein kinase domain containing protein | 0.0012 | 0.1043 | 0.5397 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 2820 nM | BindingDB_Patents: Inhibition Assay. Experimental was performed by measuring the formation of NADH at 340 nm with a fluorescence spectrophotometer. Specifically, 2 ml (in total) of the solution containing 50 mM Tris-HCl (pH 7.5), 0.1 mM DTT, 0.25 mM NAD+, 10 µg of purified 15-PGDH enzyme, 21 µM PGE2 and various concentrations (0.0001 µM to 64 µM) of the derivatives according to the present invention was added to each cell. The absorbance of the reaction mixture was recorded at 340 nm so that the activities of the derivatives according to the present invention as 15-PGDH inhibitors were determined from a standard curve prepared from the absorbance of various concentrations of NADH at 340 nm. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.